[go: up one dir, main page]

CO2018001840A2 - Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 - Google Patents

Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5

Info

Publication number
CO2018001840A2
CO2018001840A2 CONC2018/0001840A CO2018001840A CO2018001840A2 CO 2018001840 A2 CO2018001840 A2 CO 2018001840A2 CO 2018001840 A CO2018001840 A CO 2018001840A CO 2018001840 A2 CO2018001840 A2 CO 2018001840A2
Authority
CO
Colombia
Prior art keywords
antibodies
compositions
biopharmaceutical compositions
biopharmaceutical
mepolizumab
Prior art date
Application number
CONC2018/0001840A
Other languages
English (en)
Inventor
Myrna A Monck
Narendra B Bam
Jennifer Dally
Michelle Spatara
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018001840(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CO2018001840A2 publication Critical patent/CO2018001840A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a composiciones que comprenden anticuerpos, adecuadas para el mantenimiento de la función biológica de mepolizumab y para el tratamiento de enfermedades mediadas por IL-5.
CONC2018/0001840A 2015-08-24 2018-02-22 Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 CO2018001840A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02
PCT/IB2016/055012 WO2017033121A1 (en) 2015-08-24 2016-08-22 Biopharmaceutical compositions

Publications (1)

Publication Number Publication Date
CO2018001840A2 true CO2018001840A2 (es) 2018-05-31

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0001840A CO2018001840A2 (es) 2015-08-24 2018-02-22 Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5

Country Status (22)

Country Link
US (10) US10870695B2 (es)
EP (2) EP4056590A1 (es)
JP (4) JP6821659B2 (es)
KR (2) KR20240099511A (es)
CN (5) CN108137683A (es)
AU (1) AU2016311385C1 (es)
BR (1) BR112018003741A2 (es)
CA (1) CA2996088A1 (es)
CL (1) CL2018000499A1 (es)
CO (1) CO2018001840A2 (es)
CR (1) CR20180115A (es)
DO (1) DOP2018000057A (es)
EA (1) EA037487B1 (es)
IL (1) IL257539A (es)
MA (1) MA42692A (es)
MX (2) MX2018002319A (es)
PE (1) PE20181176A1 (es)
PH (1) PH12018500379B1 (es)
TW (2) TWI780988B (es)
UY (1) UY36868A (es)
WO (1) WO2017033121A1 (es)
ZA (1) ZA201801158B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976113B2 (en) 2017-05-26 2024-05-07 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137683A (zh) 2015-08-24 2018-06-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
RU2758008C2 (ru) 2016-12-23 2021-10-25 Сефалон, Инк. Анти-il-5 антитела
CN110913887A (zh) * 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
EP3689906A4 (en) 2017-09-29 2021-04-07 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODY IL-5, ITS ANTIGEN BINDING FRAGMENT AND ITS MEDICAL USE
WO2019224724A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
KR20210145187A (ko) 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
JP2023507981A (ja) * 2019-12-18 2023-02-28 テサロ， インコーポレイテッド 生物医薬組成物および関連の方法
EP4272756A4 (en) * 2021-02-05 2024-12-11 Bio-Thera Solutions, Ltd. ANTI-IL-5 ANTIBODY FORMULATION, MANUFACTURING METHOD AND USE THEREOF
IL309997A (en) * 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
EP4405383A1 (en) * 2021-09-22 2024-07-31 Sonoma Biotherapeutics, Inc. Il5ra cell surface markers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ291039B6 (cs) 1992-02-06 2002-12-11 Schering Corporation Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
ATE346867T1 (de) 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
DK1988910T3 (en) 2006-02-28 2018-01-22 Kodiak Sciences Inc ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof
EP2152290B1 (en) 2007-04-30 2014-06-04 GlaxoSmithKline LLC Methods for administering anti-il-5 antibodies
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
TW200944231A (en) * 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0910854A2 (pt) 2008-03-28 2015-10-06 Glaxosmithkline Llc métodos de tratamento
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
CN102711756A (zh) 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
US10286037B2 (en) 2011-02-09 2019-05-14 Glaxosmithkline Llc Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
CA2832556A1 (en) 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
CA2832560A1 (en) 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
KR20150129033A (ko) * 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
WO2015049519A2 (en) 2013-10-02 2015-04-09 Vectura Limited Method and apparatus
EP3097122B9 (en) 2014-01-24 2020-11-11 NGM Biopharmaceuticals, Inc. Antibodies binding beta klotho domain 2 and methods of use thereof
CN106536551B (zh) 2014-02-06 2021-04-16 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
CN108137683A (zh) 2015-08-24 2018-06-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976113B2 (en) 2017-05-26 2024-05-07 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins

Also Published As

Publication number Publication date
WO2017033121A1 (en) 2017-03-02
CA2996088A1 (en) 2017-03-02
MX2018002319A (es) 2018-04-11
US20220380452A1 (en) 2022-12-01
US20210340246A1 (en) 2021-11-04
UY36868A (es) 2017-03-31
AU2016311385C1 (en) 2019-08-22
JP6821659B2 (ja) 2021-01-27
EA037487B1 (ru) 2021-04-02
US12187789B2 (en) 2025-01-07
EP4056590A1 (en) 2022-09-14
DOP2018000057A (es) 2018-03-15
TWI750133B (zh) 2021-12-21
CN116327923A (zh) 2023-06-27
TW201722473A (zh) 2017-07-01
EP3341409A1 (en) 2018-07-04
PH12018500379A1 (en) 2018-09-03
IL257539A (en) 2018-04-30
US10870695B2 (en) 2020-12-22
US12187791B2 (en) 2025-01-07
JP7463070B2 (ja) 2024-04-08
CN116327921A (zh) 2023-06-27
US20220185878A1 (en) 2022-06-16
TWI780988B (zh) 2022-10-11
US20200199219A1 (en) 2020-06-25
ZA201801158B (en) 2019-08-28
KR20240099511A (ko) 2024-06-28
US20240294630A1 (en) 2024-09-05
US11286298B2 (en) 2022-03-29
CN108137683A (zh) 2018-06-08
US12187790B2 (en) 2025-01-07
US20210340247A1 (en) 2021-11-04
US11274148B2 (en) 2022-03-15
CL2018000499A1 (es) 2018-07-06
JP2024123040A (ja) 2024-09-10
US11459384B2 (en) 2022-10-04
CN116327922A (zh) 2023-06-27
AU2016311385A1 (en) 2018-03-15
JP2020033351A (ja) 2020-03-05
EA201890572A1 (ru) 2018-10-31
JP2022023049A (ja) 2022-02-07
KR20180037275A (ko) 2018-04-11
TW202233238A (zh) 2022-09-01
JP2018526369A (ja) 2018-09-13
MX2024001617A (es) 2024-03-06
US11299541B2 (en) 2022-04-12
CN116474091A (zh) 2023-07-25
PH12018500379B1 (en) 2022-11-23
US20210332125A1 (en) 2021-10-28
CR20180115A (es) 2018-04-12
AU2016311385B2 (en) 2019-05-09
US20240294628A1 (en) 2024-09-05
BR112018003741A2 (pt) 2018-09-25
US20240294629A1 (en) 2024-09-05
US20180251539A1 (en) 2018-09-06
MA42692A (fr) 2018-07-04
PE20181176A1 (es) 2018-07-20

Similar Documents

Publication Publication Date Title
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
SV2018005610A (es) Derivados de oxopiridina sustituidos
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2017000806A1 (es) Compuestos anti-tnf
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
ECSP17064695A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
BR112016025470A2 (pt) ?hdl terapêutico?
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2017006167A (es) Compuestos que interactúan con glicanos y métodos de uso.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2019001736A1 (es) Polimorfos.
CL2019001737A1 (es) Polimorfos.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
UY36221A (es) Derivados de isoindolinona